Skip to main content
Erschienen in: CardioVascular and Interventional Radiology 5/2016

08.03.2016 | Clinical Investigation

Correlation of Peripheral Vein Tumour Marker Levels, Internal Iliac Vein Tumour Marker Levels and Radical Prostatectomy Specimens in Patients with Prostate Cancer and Borderline High Prostate-Specific Antigen: A Pilot Study

verfasst von: Cormac Farrelly, Priti Lal, Scott O. Trerotola, Gregory J. Nadolski, Micah M. Watts, Catherine Mc. Gorrian, Thomas J. Guzzo

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To correlate prostate-specific antigen (PSA), free to total PSA percentage (fPSA%) and prostatic acid phosphatase (PAP) levels from peripheral and pelvic venous samples with prostatectomy specimens in patients with prostate adenocarcinoma and borderline elevation of PSA.

Materials and Methods

In this prospective institutional review board approved study, 7 patients with biopsy proven prostate cancer had a venous sampling procedure prior to prostatectomy (mean 3.2 days, range 1–7). Venous samples were taken from a peripheral vein (PVS), the right internal iliac vein, a deep right internal iliac vein branch, left internal iliac vein and a deep left internal iliac vein branch. Venous sampling results were compared to tumour volume, laterality, stage and grade in prostatectomy surgical specimens.

Results

Mean PVS PSA was 4.29, range 2.3–6 ng/ml. PSA and PAP values in PVS did not differ significantly from internal iliac or deep internal iliac vein samples (p > 0.05). fPSA% was significantly higher in internal iliac (p = 0.004) and deep internal iliac (p = 0.003) vein samples compared to PVS. One of 7 patients had unilateral tumour only. This patient, with left–sided tumour, had a fPSA% of 6, 6, 6, 14 and 12 in his peripheral, right internal iliac, deep right internal iliac branch, left internal iliac and deep left internal iliac branch samples respectively. There were no adverse events.

Conclusion

fPSA%, unlike total PSA or PAP, is significantly higher in pelvic vein compared to peripheral vein samples when prostate cancer is present. Larger studies including patients with higher PSA values are warranted to further investigate this counterintuitive finding.
Literatur
1.
2.
Zurück zum Zitat Carrol PR. Early stage prostate cancer-do we have a problem with over-detection, overtreatment or both? J Urol. 2005;173(4):1061–2.CrossRef Carrol PR. Early stage prostate cancer-do we have a problem with over-detection, overtreatment or both? J Urol. 2005;173(4):1061–2.CrossRef
3.
Zurück zum Zitat Mouraviev V, Mayes JM, Madden JF, Sun L, Polascik TJ. Analysis of laterality and percentage of tumor involvement in 1386 prostatectomized specimens for selection of unilateral focal cryotherapy. Tech Cancer Res Treat. 2007;6(2):91–6.CrossRef Mouraviev V, Mayes JM, Madden JF, Sun L, Polascik TJ. Analysis of laterality and percentage of tumor involvement in 1386 prostatectomized specimens for selection of unilateral focal cryotherapy. Tech Cancer Res Treat. 2007;6(2):91–6.CrossRef
4.
Zurück zum Zitat Djavan B, Susani M, Bursa B, Basharkhah A, Simak R, Marberger M. Predictability and significance of multifocal cancer in the radical prostatectomy specimen. Techn Urol. 1999;5(3):139–42.CrossRef Djavan B, Susani M, Bursa B, Basharkhah A, Simak R, Marberger M. Predictability and significance of multifocal cancer in the radical prostatectomy specimen. Techn Urol. 1999;5(3):139–42.CrossRef
5.
Zurück zum Zitat Polascik TJ, Mayers JM, Sun L, Madden JF, Moul JW, Mouraviev V. Pathologic stage 2a and 2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate. 2008;68(13):1380–6.CrossRefPubMed Polascik TJ, Mayers JM, Sun L, Madden JF, Moul JW, Mouraviev V. Pathologic stage 2a and 2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate. 2008;68(13):1380–6.CrossRefPubMed
7.
Zurück zum Zitat Polascik TJ, Mouraviev V. Focal therapy for prostate cancer is a reasonable treatment option in properly selected patients. Urology. 2009;74(4):726–30.CrossRefPubMed Polascik TJ, Mouraviev V. Focal therapy for prostate cancer is a reasonable treatment option in properly selected patients. Urology. 2009;74(4):726–30.CrossRefPubMed
8.
Zurück zum Zitat Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, for the International task force on prostate cancer and the focal lesion paradigm, et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007;178(6):2260–7.CrossRefPubMed Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, for the International task force on prostate cancer and the focal lesion paradigm, et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007;178(6):2260–7.CrossRefPubMed
9.
Zurück zum Zitat Scardino PT, Abenhaim LL. Focal therapy for prostate cancer: analysis by an international panel. Urology. 2008;72(6 Suppl):S1–2.CrossRefPubMed Scardino PT, Abenhaim LL. Focal therapy for prostate cancer: analysis by an international panel. Urology. 2008;72(6 Suppl):S1–2.CrossRefPubMed
10.
Zurück zum Zitat Mendez MH, Joh DY, Gupta R, Polascik TJ. Current trends and new frontiers in focal therapy for localized prostate cancer. Curr Urol Rep. 2015;16(6):35.CrossRefPubMed Mendez MH, Joh DY, Gupta R, Polascik TJ. Current trends and new frontiers in focal therapy for localized prostate cancer. Curr Urol Rep. 2015;16(6):35.CrossRefPubMed
11.
12.
Zurück zum Zitat Wendell-Smith C. Terminology of the prostate and related structures. Clin Anat. 2000;13(3):207–13.CrossRefPubMed Wendell-Smith C. Terminology of the prostate and related structures. Clin Anat. 2000;13(3):207–13.CrossRefPubMed
13.
Zurück zum Zitat Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic diseases. JAMA. 1998;279(19):1542–7.CrossRefPubMed Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic diseases. JAMA. 1998;279(19):1542–7.CrossRefPubMed
14.
Zurück zum Zitat Djavan B, Remzi M, Zlotta AR, Ravery V, Hammerer P, Reissigl A, et al. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology. 2002;60(4 Suppl 1):4–9.CrossRefPubMed Djavan B, Remzi M, Zlotta AR, Ravery V, Hammerer P, Reissigl A, et al. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology. 2002;60(4 Suppl 1):4–9.CrossRefPubMed
15.
Zurück zum Zitat Puppo P. Repeated negative prostate biopsies with persistently elevated or rising PSA: a modern urologic dilemma. Eur Urol. 2007;52(3):639–41.CrossRefPubMed Puppo P. Repeated negative prostate biopsies with persistently elevated or rising PSA: a modern urologic dilemma. Eur Urol. 2007;52(3):639–41.CrossRefPubMed
16.
Zurück zum Zitat Jones JS. Management of rising prostate-specific antigen following a negative biopsy. Curr Opin Urol. 2010;20(3):198–203.CrossRefPubMed Jones JS. Management of rising prostate-specific antigen following a negative biopsy. Curr Opin Urol. 2010;20(3):198–203.CrossRefPubMed
17.
Zurück zum Zitat Trock BJ. Circulating biomarkers for discriminating indolent from aggressive disease in prostate cancer active surveillance. Curr Opin Urol. 2014;24(3):293–302.CrossRefPubMed Trock BJ. Circulating biomarkers for discriminating indolent from aggressive disease in prostate cancer active surveillance. Curr Opin Urol. 2014;24(3):293–302.CrossRefPubMed
18.
Zurück zum Zitat Whitesel JA, Donohue RE, Mani JH, Mohr S, Scanavino DJ, Augspurger RR, et al. Acid phosphatase: its influence on the management of carcinoma of the prostate. J Urol. 1984;131(1):70–2.PubMed Whitesel JA, Donohue RE, Mani JH, Mohr S, Scanavino DJ, Augspurger RR, et al. Acid phosphatase: its influence on the management of carcinoma of the prostate. J Urol. 1984;131(1):70–2.PubMed
19.
Zurück zum Zitat Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125–32.CrossRefPubMedPubMedCentral Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125–32.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–35.CrossRefPubMedPubMedCentral Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–35.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Pinsky PF, Parnes HL, Andriole G. Mortality and complications after prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening (PLCO) trial. BJU Int. 2014;113(2):254–9.CrossRefPubMedPubMedCentral Pinsky PF, Parnes HL, Andriole G. Mortality and complications after prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening (PLCO) trial. BJU Int. 2014;113(2):254–9.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Anastasiadis E, van der Meulen J, Emberton M. Hospital admissions after transrectal ultrasound-guided biopsy of the prostate in men diagnosed with prostate cancer: a database analysis in England. Int J Urol. 2015;22(2):181–6.CrossRefPubMed Anastasiadis E, van der Meulen J, Emberton M. Hospital admissions after transrectal ultrasound-guided biopsy of the prostate in men diagnosed with prostate cancer: a database analysis in England. Int J Urol. 2015;22(2):181–6.CrossRefPubMed
23.
Zurück zum Zitat Carrol PR. Early stage prostate cancer-do we have a problem with over-detection, overtreatment or both? J Urol. 2005;173(4):1061–2.CrossRef Carrol PR. Early stage prostate cancer-do we have a problem with over-detection, overtreatment or both? J Urol. 2005;173(4):1061–2.CrossRef
25.
Zurück zum Zitat Lau JH, Drake W, Matson M. The current role of venous sampling in the localization of endocrine disease. Cardiovasc Intervent Radiol. 2007;30(4):555–70.CrossRefPubMed Lau JH, Drake W, Matson M. The current role of venous sampling in the localization of endocrine disease. Cardiovasc Intervent Radiol. 2007;30(4):555–70.CrossRefPubMed
26.
Zurück zum Zitat Young W, Stanson A, Thompson G, et al. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004;136(6):1227–35.CrossRefPubMed Young W, Stanson A, Thompson G, et al. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004;136(6):1227–35.CrossRefPubMed
27.
Zurück zum Zitat Ginsburg M, Christoforidis GA, Zivin SP, Obara P, Wroblewski K, Angelos P, et al. Adenoma localization for recurrent or persistent primary hyperparathyroidism using dynamic four-dimensional CT and venous sampling. J Vasc Interv Radiol. 2015;26(1):79–86.CrossRefPubMed Ginsburg M, Christoforidis GA, Zivin SP, Obara P, Wroblewski K, Angelos P, et al. Adenoma localization for recurrent or persistent primary hyperparathyroidism using dynamic four-dimensional CT and venous sampling. J Vasc Interv Radiol. 2015;26(1):79–86.CrossRefPubMed
28.
Zurück zum Zitat Kaltsas G, Mukherjee J, Kola B, Isidori AM, Hanson JA, Dacie JE, et al. Is ovarian and adrenal venous catheterization and sampling helpful in the investigation of hyperandrogenic women? Clin Endocrinol. 2003;59(1):34–43.CrossRef Kaltsas G, Mukherjee J, Kola B, Isidori AM, Hanson JA, Dacie JE, et al. Is ovarian and adrenal venous catheterization and sampling helpful in the investigation of hyperandrogenic women? Clin Endocrinol. 2003;59(1):34–43.CrossRef
29.
Zurück zum Zitat Agarwal MD, Trerotola SO. Combined adrenal and ovarian venous sampling to localize an androgen producing tumor. Cardiovasc Intervent Radiol. 2010;33(6):1266–9.CrossRefPubMed Agarwal MD, Trerotola SO. Combined adrenal and ovarian venous sampling to localize an androgen producing tumor. Cardiovasc Intervent Radiol. 2010;33(6):1266–9.CrossRefPubMed
30.
31.
Zurück zum Zitat Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2013;189(1 Suppl):2–11.CrossRef Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2013;189(1 Suppl):2–11.CrossRef
33.
Zurück zum Zitat Batson OV. The vertebral vein system: Caldwell Lecture, 1956. Am J Roentgenol Radium Ther Nucl Med. 1957;78(2):195–212.PubMed Batson OV. The vertebral vein system: Caldwell Lecture, 1956. Am J Roentgenol Radium Ther Nucl Med. 1957;78(2):195–212.PubMed
34.
Zurück zum Zitat Suzuki T, Kurokawa K, Jimbo H, Hayashi M, Sekihara T, Takahashi H, et al. The role of intraabdominal pressure in venous blood drainage from the prostate into the vertebral vein system. Jpn J Physiol. 1993;43(5):697–708.CrossRefPubMed Suzuki T, Kurokawa K, Jimbo H, Hayashi M, Sekihara T, Takahashi H, et al. The role of intraabdominal pressure in venous blood drainage from the prostate into the vertebral vein system. Jpn J Physiol. 1993;43(5):697–708.CrossRefPubMed
35.
Zurück zum Zitat Franks LM. The spread of prostatic carcinoma to the bones. J Pathol Bacteriol. 1953;66:91–3.CrossRefPubMed Franks LM. The spread of prostatic carcinoma to the bones. J Pathol Bacteriol. 1953;66:91–3.CrossRefPubMed
36.
Zurück zum Zitat McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology. 1995;45(5):729–44.CrossRefPubMed McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology. 1995;45(5):729–44.CrossRefPubMed
37.
Zurück zum Zitat Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic diseases. JAMA. 1998;279(19):1542–7.CrossRefPubMed Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic diseases. JAMA. 1998;279(19):1542–7.CrossRefPubMed
38.
Zurück zum Zitat Richardson TD, Wojno KJ, Liang LW, Giacherio DA, England BG, Henricks WH, et al. Half-life determination of serum free prostate-specific antigen following radical retropubic prostatectomy. Urology. 1996;48(6A Suppl):40–4.CrossRefPubMed Richardson TD, Wojno KJ, Liang LW, Giacherio DA, England BG, Henricks WH, et al. Half-life determination of serum free prostate-specific antigen following radical retropubic prostatectomy. Urology. 1996;48(6A Suppl):40–4.CrossRefPubMed
39.
Zurück zum Zitat Turkbey B, Albert PS, Kurdziel K, Choyke PL. Imaging localized prostate cancer: current approaches and new developments. AJR. 2009;192(6):1471–80.CrossRefPubMedPubMedCentral Turkbey B, Albert PS, Kurdziel K, Choyke PL. Imaging localized prostate cancer: current approaches and new developments. AJR. 2009;192(6):1471–80.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Hamoen EH, de Rooij M, Witjes JA, Barentsz JO, Rovers MM. Use of the prostate imaging reporting and data system (PI-RADS) for prostate cancer detection with multiparametric magnetic resonance imaging: a diagnostic meta-analysis. Eur Urol. 2015;67(6):1112–21.CrossRefPubMed Hamoen EH, de Rooij M, Witjes JA, Barentsz JO, Rovers MM. Use of the prostate imaging reporting and data system (PI-RADS) for prostate cancer detection with multiparametric magnetic resonance imaging: a diagnostic meta-analysis. Eur Urol. 2015;67(6):1112–21.CrossRefPubMed
41.
Zurück zum Zitat Blomqvist L, Carlsson S, Gjertsson P, Heintz E, Hultcrantz M, Mejare I, et al. Limited evidence for the use of imaging to detect prostate cancer: a systematic review. Eur J Radiol. 2014;83(9):1601–6.CrossRefPubMed Blomqvist L, Carlsson S, Gjertsson P, Heintz E, Hultcrantz M, Mejare I, et al. Limited evidence for the use of imaging to detect prostate cancer: a systematic review. Eur J Radiol. 2014;83(9):1601–6.CrossRefPubMed
42.
Zurück zum Zitat Schoots IG, Petrides N, Giganti F, Bokhorst LP, Rannikko A, Klotz L, et al. Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. Eur Urol. 2015;67(4):627–36.CrossRefPubMed Schoots IG, Petrides N, Giganti F, Bokhorst LP, Rannikko A, Klotz L, et al. Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. Eur Urol. 2015;67(4):627–36.CrossRefPubMed
44.
Zurück zum Zitat Falzarano SM, Ferro M, Bollito E, Klein EA, Carrieri G, Magi-Galluzzi C. Novel biomarkers and genomic tests in prostate cancer: a critical analysis. Minerva Urol Nefrol. 2015;67(3):211–31.PubMed Falzarano SM, Ferro M, Bollito E, Klein EA, Carrieri G, Magi-Galluzzi C. Novel biomarkers and genomic tests in prostate cancer: a critical analysis. Minerva Urol Nefrol. 2015;67(3):211–31.PubMed
Metadaten
Titel
Correlation of Peripheral Vein Tumour Marker Levels, Internal Iliac Vein Tumour Marker Levels and Radical Prostatectomy Specimens in Patients with Prostate Cancer and Borderline High Prostate-Specific Antigen: A Pilot Study
verfasst von
Cormac Farrelly
Priti Lal
Scott O. Trerotola
Gregory J. Nadolski
Micah M. Watts
Catherine Mc. Gorrian
Thomas J. Guzzo
Publikationsdatum
08.03.2016
Verlag
Springer US
Erschienen in
CardioVascular and Interventional Radiology / Ausgabe 5/2016
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-016-1322-5

Weitere Artikel der Ausgabe 5/2016

CardioVascular and Interventional Radiology 5/2016 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.